GLP-1 Drugs for Psychiatric Illness: A Scoping Review of the Evidence
Scoping review of GLP-1 agonist efficacy in psychiatric illnesses covers schizophrenia, depression, bipolar disorder, and addiction, finding emerging evidence for metabolic and possibly direct neuropsychiatric benefits.
Quick Facts
What This Study Found
Scoping review of GLP-1 agonist efficacy in psychiatric illnesses covers schizophrenia, depression, bipolar disorder, and addiction, finding emerging evidence for metabolic and possibly direct neuropsychiatric benefits.
Key Numbers
Review covered studies on GLP-1 drugs across depression, schizophrenia, substance use disorders, and other psychiatric conditions.
How They Did This
Study methodology detailed in the full publication.
Why This Research Matters
These findings have practical implications for the growing number of patients using peptide-based therapies.
The Bigger Picture
This study contributes to the expanding evidence for peptide therapeutics in clinical practice.
What This Study Doesn't Tell Us
Study limitations in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to other evidence?
- ?What further research is needed?
Trust & Context
- Key Stat:
- Key finding Scoping review of GLP-1 agonist efficacy in psychiatric illnesses covers schizophrenia, depression,
- Evidence Grade:
- Evidence level based on study design in publication.
- Study Age:
- Published in 2025.
- Original Title:
- Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.
- Published In:
- The primary care companion for CNS disorders, 27(3) (2025)
- Authors:
- Ali, Mohsan, Ahmed, Ayesha, Khan, Basim Ahmed, Shah, Syeda Taleha, Naveed, Sadiq, Ashraf, Nauman
- Database ID:
- RPEP-09864
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean for patients?
Scoping review of GLP-1 agonist efficacy in psychiatric illnesses covers schizophrenia, depression, bipolar disorder, and addiction, finding emerging evidence for metabolic and possibly direct neuropsychiatric benefits.
How reliable is this?
Consult the full publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09864APA
Ali, Mohsan; Ahmed, Ayesha; Khan, Basim Ahmed; Shah, Syeda Taleha; Naveed, Sadiq; Ashraf, Nauman. (2025). Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.. The primary care companion for CNS disorders, 27(3). https://doi.org/10.4088/PCC.24nr03828
MLA
Ali, Mohsan, et al. "Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scoping Review.." The primary care companion for CNS disorders, 2025. https://doi.org/10.4088/PCC.24nr03828
RethinkPeptides
RethinkPeptides Research Database. "Efficacy of GLP-1 Agonists in Psychiatric Illnesses: A Scopi..." RPEP-09864. Retrieved from https://rethinkpeptides.com/research/ali-2025-efficacy-of-glp1-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.